Compare Stocks: IMMP, SION, CGEN, and TARA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.41	$2.25	$1.29 ▼ $3.23	$227.87M	2.77	257,219 shs	191,226 shs
IMMP Prima BioMed	$0.38 -5.8%	$0.40	$0.29 ▼ $3.53	$56M	2.25	190,286 shs	64,202 shs
SION Sionna Therapeutics	$6.46 -1.2%	$39.18	$4.01 ▼ $54.97	$292.07M	1.33	3.93 million shs	2.86 million shs
TARA Protara Therapeutics	$3.97 +0.8%	$4.02	$2.97 ▼ $7.82	$234.61M	1.5	394,483 shs	333,029 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	0.00%	0.00%	+3.43%	-12.36%	+62.84%
IMMP Prima BioMed	0.00%	-1.50%	-12.76%	-26.88%	-78.03%
SION Sionna Therapeutics	0.00%	-87.34%	-85.74%	-83.94%	-69.11%
TARA Protara Therapeutics	0.00%	-3.64%	-2.70%	-22.16%	+21.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.41	$2.25	$1.29 ▼ $3.23	$227.87M	2.77	257,219 shs	191,226 shs
IMMP Prima BioMed	$0.38 -5.8%	$0.40	$0.29 ▼ $3.53	$56M	2.25	190,286 shs	64,202 shs
SION Sionna Therapeutics	$6.46 -1.2%	$39.18	$4.01 ▼ $54.97	$292.07M	1.33	3.93 million shs	2.86 million shs
TARA Protara Therapeutics	$3.97 +0.8%	$4.02	$2.97 ▼ $7.82	$234.61M	1.5	394,483 shs	333,029 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	0.00%	0.00%	+3.43%	-12.36%	+62.84%
IMMP Prima BioMed	0.00%	-1.50%	-12.76%	-26.88%	-78.03%
SION Sionna Therapeutics	0.00%	-87.34%	-85.74%	-83.94%	-69.11%
TARA Protara Therapeutics	0.00%	-3.64%	-2.70%	-22.16%	+21.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$5.00	107.47% Upside
IMMP Prima BioMed	2.00	Hold	$5.50	1,347.37% Upside
SION Sionna Therapeutics	2.00	Hold	$42.22	553.59% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	561.21% Upside

Current Analyst Ratings Breakdown

Latest IMMP, SION, CGEN, and TARA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	SION Sionna Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/10/2026	SION Sionna Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	SION Sionna Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	SION Sionna Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/10/2026	SION Sionna Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/10/2026	SION Sionna Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/10/2026	SION Sionna Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
8/10/2026	SION Sionna Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Sector Perform	$5.00
8/10/2026	SION Sionna Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$5.00
8/10/2026	SION Sionna Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00
8/5/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$72.76M	3.13	$0.37 per share	6.45	$0.94 per share	2.56
IMMP Prima BioMed	$6.69M	8.37	N/A	N/A	$0.63 per share	0.60
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	$5.88 per share	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$2.73 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	$35.34M	$0.38	6.34	N/A	N/A	47.56%	42.57%	26.13%	N/A
IMMP Prima BioMed	-$39.78M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
SION Sionna Therapeutics	-$75.27M	-$2.18	N/A	N/A	N/A	N/A	-32.94%	-31.08%	N/A
TARA Protara Therapeutics	-$57.44M	-$1.35	N/A	N/A	N/A	N/A	-41.72%	-38.78%	N/A

Latest IMMP, SION, CGEN, and TARA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	H2 2026	IMMP Prima BioMed	-$0.0258	N/A	N/A	N/A	$11.73 million	N/A
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A
8/6/2026	Q2 2026	SION Sionna Therapeutics	-$0.64	-$0.66	-$0.02	-$0.66	N/A	N/A
8/3/2026	Q2 2026	CGEN Compugen	-$0.08	-$0.07	+$0.01	-$0.07	$1.29 million	$2.60 million
5/18/2026	Q1 2026	CGEN Compugen	-$0.07	-$0.08	-$0.01	-$0.08	$1.57 million	$2.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	5.72	5.72
IMMP Prima BioMed	N/A	2.97	N/A
SION Sionna Therapeutics	N/A	20.05	20.05
TARA Protara Therapeutics	N/A	10.97	15.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
IMMP Prima BioMed	2.32%
SION Sionna Therapeutics	N/A
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
IMMP Prima BioMed	3.07%
SION Sionna Therapeutics	5.10%
TARA Protara Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	94.55 million	85.57 million	Optionable
IMMP Prima BioMed	2,021	147.37 million	142.85 million	Optionable
SION Sionna Therapeutics	35	45.21 million	42.91 million	N/A
TARA Protara Therapeutics	30	59.10 million	54.60 million	Optionable

IMMP, SION, CGEN, and TARA Headlines

Recent News About These Companies

HC Wainwright Has Pessimistic Outlook of TARA Q3 Earnings

August 16 at 1:13 AM | americanbankingnews.com

Protara Therapeutics (NASDAQ:TARA) Stock Rating Lowered by Wall Street Zen

August 15 at 1:51 AM | americanbankingnews.com

Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen

August 15 at 1:47 AM | marketbeat.com

HC Wainwright Issues Negative Forecast for TARA Earnings

August 14 at 8:11 AM | marketbeat.com

Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA

August 14 at 3:27 AM | marketbeat.com

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

August 12, 2026 | markets.businessinsider.com

Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results

August 11, 2026 | marketbeat.com

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

August 11, 2026 | seekingalpha.com

Protara Therapeutics (TARA) Expected to Release Quarterly Earnings on Monday

August 9, 2026 | americanbankingnews.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages

August 4, 2026 | marketbeat.com

Protara Therapeutics (TARA) Projected to Announce Quarterly Earnings on Monday

August 3, 2026 | marketbeat.com

Walleye Capital LLC Boosts Position in Protara Therapeutics, Inc. $TARA

July 24, 2026 | marketbeat.com

What Makes Protara Therapeutics (TARA) a New Buy Stock

July 21, 2026 | zacks.com

Protara Therapeutics Announces Key Medical Leadership Transition

June 29, 2026 | tipranks.com

Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright

May 21, 2026 | theglobeandmail.com

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026 | globenewswire.com

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

May 19, 2026 | seekingalpha.com

Protara’s cell therapy shows treatment durability in mid-stage NMIBC study

May 19, 2026 | msn.com

Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program

May 18, 2026 | quiverquant.comQ

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026 | globenewswire.com

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of ...

May 15, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMMP, SION, CGEN, and TARA Company Descriptions

Compugen NASDAQ:CGEN

$2.41 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.37 -0.04 (-1.87%)

As of 08/14/2026 07:34 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Prima BioMed NASDAQ:IMMP

$0.38 -0.02 (-5.82%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+0.26%)

As of 08/14/2026 07:22 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Sionna Therapeutics NASDAQ:SION

$6.46 -0.08 (-1.22%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$6.38 -0.08 (-1.25%)

As of 08/14/2026 07:59 PM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.

Protara Therapeutics NASDAQ:TARA

$3.97 +0.03 (+0.76%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.98 +0.00 (+0.13%)

As of 08/14/2026 07:55 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMP, SION, CGEN, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMP, SION, CGEN, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMP, SION, CGEN, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMMP, SION, CGEN, and TARA Company Descriptions

Compugen NASDAQ:CGEN

Prima BioMed NASDAQ:IMMP

Sionna Therapeutics NASDAQ:SION

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMP, SION, CGEN, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMP, SION, CGEN, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMP, SION, CGEN, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMMP, SION, CGEN, and TARA Company Descriptions

Compugen NASDAQ:CGEN

Prima BioMed NASDAQ:IMMP

Sionna Therapeutics NASDAQ:SION

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools